Sifferlen Thierry, Boller Amandine, Chardonneau Audrey, Cottreel Emmanuelle, Gatfield John, Treiber Alexander, Roch Catherine, Jenck Francois, Aissaoui Hamed, Williams Jodi T, Brotschi Christine, Heidmann Bibia, Siegrist Romain, Boss Christoph
Actelion Pharmaceuticals Ltd, Drug Discovery and Preclinical Research & Development, Gewerbestrasse 16, CH-4123 Allschwil, Switzerland.
Actelion Pharmaceuticals Ltd, Drug Discovery and Preclinical Research & Development, Gewerbestrasse 16, CH-4123 Allschwil, Switzerland.
Bioorg Med Chem Lett. 2015 May 1;25(9):1884-91. doi: 10.1016/j.bmcl.2015.03.035. Epub 2015 Mar 21.
Starting from advanced pyrrolidin-2-one lead compounds, this novel series of small-molecule orexin receptor antagonists was further optimized by fine-tuning of the C-3 substitution at the γ-lactam ring. We discuss our design to align in vitro potency with metabolic stability and improved physicochemical/pharmacokinetic properties while avoiding P-glycoprotein-mediated efflux. These investigations led to the identification of the orally active 3-hydroxypyrrolidin-2-one 46, a potent and selective orexin-2 receptor antagonist, that achieved good brain exposure and promoted physiological sleep in rats.
从先进的吡咯烷-2-酮先导化合物开始,通过对γ-内酰胺环上C-3取代基的微调,对这一系列新型小分子食欲素受体拮抗剂进行了进一步优化。我们讨论了我们的设计,以使体外效力与代谢稳定性以及改善的物理化学/药代动力学性质相匹配,同时避免P-糖蛋白介导的外排。这些研究导致鉴定出具有口服活性的3-羟基吡咯烷-2-酮46,一种强效且选择性的食欲素-2受体拮抗剂,其在大鼠中实现了良好的脑内暴露并促进了生理性睡眠。